We recently published a list of 20 Most Expensive Stocks Insiders Are Dumping In March. In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against other most expensive stocks insiders are dumping in March.

After being in the green for a few trading sessions, the broader market index slid 0.8% on Wednesday, and blue-chip companies declined 0.1%. The NASDAQ Composite was down 1.6% in the early afternoon. On Tuesday, Trump provided an update on tariffs, saying they will likely be more “lenient than reciprocal,” suggesting a more relaxed approach, reports CNBC.

As investors process daily market developments, uncertainty continues to impact the market. In these periods, insider trading often attracts attention, as purchases of company stock by executives may suggest confidence in the company’s future. However, insider selling doesn’t necessarily imply a lack of faith—it may be driven by personal financial needs or a desire for diversification. Executives frequently rely on pre-established plans, such as 10b5-1, to maintain transparency. While insider trading can provide useful insights, it should be evaluated in the context of a company’s financial health, market trends, and industry changes.

What are some of the most expensive stocks insiders have been selling this month so far? To find out, we used Insider Monkey’s insider trading stock screener, focusing only on stocks where at least three insiders had sold shares in March. From there, we ranked the 20 stocks with the highest average price per share in times of sales.

Our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds, focusing on insider trading and stock picks from hedge fund investor newsletters and conferences. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).

With each stock, we note the average price per share of these sales and the stock’s market capitalization.

A pharmacist delivering a specific medication to a patient in a specialty pharmacy.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Market Capitalization: $130.72 billion

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is a biotechnology company focused on developing therapies for cystic fibrosis (CF) and other diseases. It markets several CF treatments, including TRIKAFTA/KAFTRIO, ALYFTREK, and ORKAMBI, and is also developing therapies for sickle cell disease, type 1 diabetes, and other conditions. The Boston, Massachusetts-based company collaborates with CRISPR Therapeutics, Moderna, and Entrada Therapeutics, and sells its products through specialty pharmacies and distributors.

For the full year 2024, Vertex (NASDAQ:VRTX) disclosed product revenue of $11.02 billion, up 12% year-over-year. The revenue growth was primarily driven by the continued performance of TRIKAFTA/KAFTRIO. Net product revenue increased 11% to $4.34 billion outside the U.S. on strong patient demand in both established and newer markets. GAAP net loss and non-GAAP net income were $536 million and $111 million, respectively, compared to GAAP net income of $3.6 billion and non-GAAP net income of $4.0 billion, respectively, for 2023.

For the full year 2025, Vertex (NASDAQ:VRTX) projects revenue to be in the range of $11.75 billion to $12 billion.

In recent developments, Vertex announced that the United Kingdom Medicines and Healthcare Products Regulatory Agency (MHRA) has granted approval for ALYFTREK, a once-daily treatment for cystic fibrosis. It is for people aged 6 and older with at least one F508del mutation or another responsive mutation in the CFTR gene.

In March, three insiders, including the CSO and CFO sold approximately $10.09 million worth of Vertex Pharmaceuticals shares at an average price of $497.58 per share. Year-to-date, the stock is up 26.41%, trading at $509.04 per share. Over the past 12 months, its shares returned 21.65%.

Twenty-six analysts rate Vertex (NASDAQ:VRTX) as “Moderate Buy” with a price target of $506.70 per share, according to MarketBeat. The average price target suggests a downside of 0.46% from the latest price.

Read here what Mad Money host Jim Cramer recently said about Vertex stock.

Overall, VRTX ranks 9th on our list of most expensive stocks insiders are dumping in March. While we acknowledge the potential of VRTX our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than VRTX but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. This article is originally published at Insider Monkey.